Budesonide inhalation 90/180 mcg — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Asthma

• Albuterol HFA
• Montelukast
• Albuterol HFA 90 mcg/actuation inhaler
• Montelukast 4/5/10 mg tabs

What Budesonide inhalation 90/180 mcg is approved for (FDA label)

PULMICORT FLEXHALER is a corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm ( 1 ) 1.1 Treatment of Asthma PULMICORT FLEXHALER is indicated for the maintenance treatment of asthma as prophylactic therapy in patients six years of age or older. Limitations of Use: • PULMICORT FLEXHALER is NOT indicated for the relief of acute bronchospasm.

Source: Read the full FDA label on DailyMed. Label effective date: January 29, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Budesonide inhalation 90/180 mcg (FDA label)

PULMICORT FLEXHALER is available as a dry powder for inhalation containing budesonide in the following 2 strengths: 90 mcg and 180 mcg. Each inhaler contains 60 or 120 actuations. FLEXHALER device containing budesonide (90 mcg or 180 mcg) as an inhalation powder ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66. SPL document ID: c80d7c71-8f2c-430e-a6ca-3b4dbc57451f. Label effective date: January 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Budesonide inhalation 90/180 mcg (FDA label)

Systemic and inhaled corticosteroid use may result in the following: • Candida albicans Infection [see Warnings and Precautions (5.1) ] • Hypersensitivity Including Anaphylaxis [see Warnings and Precautions (5.3) ] • Immunosuppression [see Warnings and Precautions (5.4) ] • Hypercorticism and Adrenal Suppression [see Warnings and Precautions (5.6) ] • Reduction in Bone Mineral Density [see Warnings and Precautions (5.8) ] • Growth Effects [see Warnings and Precautions (5.9) , Use in Specific Populations (8.4) ] • Glaucoma and Cataracts [see Warnings and Precautions (5.10) ] • Eosinophilic Conditions and Churg-Strauss [see Warnings and Precautions (5.12) ] Most common adverse reactions (incidence ≥1%) are nasopharyngitis, nasal congestion, pharyngitis, rhinitis allergic, viral upper respiratory tract infection, nausea, viral gastroenteritis, otitis media, oral candidiasis ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact the Safety Call Center at 1-888-994-8116 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66. SPL document ID: c80d7c71-8f2c-430e-a6ca-3b4dbc57451f. Label effective date: January 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Budesonide inhalation 90/180 mcg (FDA label)

The use of PULMICORT FLEXHALER is contraindicated in the following conditions: • Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. • Severe hypersensitivity to milk proteins or any ingredients of PULMICORT FLEXHALER [see Warnings and Precautions (5.3) , Description (11) ]. Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required ( 4 ) Severe hypersensitivity to milk proteins and any of the ingredients in PULMICORT FLEXHALER ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66. SPL document ID: c80d7c71-8f2c-430e-a6ca-3b4dbc57451f. Label effective date: January 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Budesonide inhalation 90/180 mcg (FDA label)

• Localized Infections: Candida albicans infection of the mouth and throat may occur. Monitor patients periodically for signs of adverse effects on the oral cavity. Advise patients to rinse the mouth following inhalation ( 5.1 ) • Deterioration of Asthma or Acute Episodes: PULMICORT FLEXHALER should not be used for relief of acute symptoms. Patients require immediate re-evaluation during rapidly deteriorating asthma ( 5.2 ) • Hypersensitivity Reactions: Anaphylaxis, rash, contact dermatitis, urticaria, angioedema, and bronchospasm have been reported with use of PULMICORT FLEXHALER. Discontinue PULMICORT FLEXHALER if such reactions occur ( 5.3 ) • Immunosuppression: Potential worsening of infections (e.g., existing tuberculosis, fungal, bacterial, viral, or parasitic infection; or ocular herpes simplex). Use with caution in patients with these infections.

Source: FDA prescribing information (DailyMed). Set ID: 5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66. SPL document ID: c80d7c71-8f2c-430e-a6ca-3b4dbc57451f. Label effective date: January 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Budesonide inhalation 90/180 mcg (FDA label)

• Strong Cytochrome P450 3A4 Inhibitors (e.g., ritonavir): Use with caution. May cause increased systemic corticosteroid effects ( 5.7 , 7.1 ) 7.1 Inhibitors of Cytochrome P450 3A4 The main route of metabolism of corticosteroids, including budesonide, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of CYP3A4 may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the co-administration of PULMICORT FLEXHALER with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see Warnings and Precautions (5.7) ] .

Source: FDA prescribing information (DailyMed). Set ID: 5d0c6c7e-2f53-4238-ab34-bd8cf49d8a66. SPL document ID: c80d7c71-8f2c-430e-a6ca-3b4dbc57451f. Label effective date: January 29, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.